Latest Breaking News On - Tarsus pharmaceuticals - Page 1 : vimarsana.com

Certain Restricted Stock Units of Tarsus Pharmaceuticals, Inc are subject to a Lock-Up Agreement Ending on 31-MAY-2024

Certain Restricted Stock Units of Tarsus Pharmaceuticals, Inc are subject to a Lock-Up Agreement Ending on 31-MAY-2024
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Certain restricted stock unitsTarsus pharmaceuticalsLock up agreement endingRestricted stock units

Tarsus to Participate in Upcoming Investor Conferences

IRVINE, Calif., May 29, 2024 Tarsus Pharmaceuticals, Inc. , whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting.

United statesJeff farrowDavid nakasoneAziz mottiwalaBobak azamianAdrienne kempCorporate communicationsTarsus pharmaceuticals incChief financialChief strategy officerChief commercial officerChief executive officerTarsus pharmaceuticalsMeibomian gland disease

Tarsus Pharmaceuticals, Inc (NASDAQ:TARS) Receives $49 88 Consensus Price Target from Brokerages

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) has been given a consensus rating of “Moderate Buy” by the eight brokerages that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12-month target price […]

United statesBryan wahlBobakr azamianArtisan partners limited partnershipHedge funds weigh in on tarsus pharmaceuticalsSecurities exchange commissionTarsus pharmaceuticals stock downJennison associatesNews ratings for tarsus pharmaceuticals dailyJefferies financial groupPricet rowe associates incGoldman sachs groupHealthcare of ontario pension plan trust fundDeerfield management companylp seriesTarsus pharmaceuticalsAnalyst recommendations for tarsus pharmaceuticals

Tarsus Pharmaceuticals, Inc (NASDAQ:TARS) Given Consensus Recommendation of Moderate Buy by Analysts

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) has received an average recommendation of “Moderate Buy” from the eight analysts that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average twelve-month price objective among brokerages […]

United statesBobakr azamianBryan wahlVanguard group incGoldman sachs groupTarsus pharmaceuticals trading downNews ratings for tarsus pharmaceuticals dailyHealthcare of ontario pension plan trust fundInstitutional trading of tarsus pharmaceuticalsTarsus pharmaceuticals incTarsus pharmaceuticalsAnalyst recommendations for tarsus pharmaceuticalsAsset management gp ltdJefferies financial groupJennison associatesSecurities exchange commission

Tarsus Pharmaceuticals (NASDAQ:TARS) Trading Down 3 6%

Tarsus Pharmaceuticals (NASDAQ:TARS) Trading Down 3 6%
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

United statesBobakr azamianBryan wahlZurcher kantonalbank zurich cantonalbankIeq capitalGoldman sachs groupTarsus pharmaceuticals company profileTarsus pharmaceuticalsJefferies financial groupTarsus pharmaceuticals stock performanceNews ratings for tarsus pharmaceuticals dailyTower research capitalRaymond james associatesChina universal asset management coTarsus pharmaceuticals incGet free report